AbbVie Inc logo

AbbVie Inc (ABBV)

Market Closed
17 Jan, 20:00
NYSE NYSE
$
171. 56
-2.14
-1.23%
Pre Market
$
171. 85
+0.29 +0.17%
323.26B Market Cap
42.2 P/E Ratio
6.2% Div Yield
7,816,400 Volume
10.28 Eps
$ 173.7
Previous Close
Day Range
171.27 173.99
Year Range
153.58 207.32
Earnings results expected in 11 days

Summary

ABBV closed Friday lower at $171.56, a decrease of 1.23% from Thursday's close, completing a monthly decrease of -3.97% or $7.1. Over the past 12 months, ABBV stock lost -3.97%.
ABBV pays dividends to its shareholders, with the most recent payment made on Nov 15, 2024. The next announced payment will be in In 3 weeks on Feb 14, 2025 for a total of $1.64.
The last earnings report, released on Oct 30, 2024, exceeded the consensus estimates by 0.08%. On average, the company has fell short of earnings expectations by -0.93%, based on the last three reports. The next scheduled earnings report is due on Jan 31, 2025.
The stock of the company had never split.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

ABBV Chart

FAQ

What Is the AbbVie Inc(ABBV) Stock Price Today?

The ABBV stock price today is $171.56.

What Stock Exchange Does AbbVie Inc Trade On?

AbbVie Inc is listed and trades on the NYSE.

What Is the Stock Symbol for AbbVie Inc?

The stock symbol for AbbVie Inc is "ABBV".

Does AbbVie Inc Pay Dividends? What's The Current Dividend Yield?

ABBV is not paying dividends to its shareholders.

What Is the AbbVie Inc Market Cap?

As of today, AbbVie Inc market cap is 323.26B.

What is AbbVie Inc Earnings Per Share?

The AbbVie Inc EPS is 0.

What Is the Next AbbVie Inc Earnings Date?

AbbVie Inc will release its next earnings report on Jan 31, 2025.

Did AbbVie Inc had any splits?

No, AbbVie Inc has never had a stock split.

AbbVie Inc Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. Robert A. Michael CEO
NYSE Exchange
US00287Y1091 ISIN
United States Country
50,000 Employees
14 Feb 2025 Last Dividend
- Last Split
2 Jan 2013 IPO Date

Overview

AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.

Products and Services

  • Humira: A therapeutic injection for various autoimmune diseases, including intestinal Behçet's disease and pyoderma gangrenosum.
  • Skyrizi: Prescribed for patients with moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease, focusing on improving skin health.
  • Rinvoq: Targets multiple conditions such as rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and several gastrointestinal diseases.
  • Imbruvica: An oral medication for adults with various blood cancers, marking significant advancements in oncology.
  • Epkinly and Elahere: Treatments tailored for different forms of lymphoma and cancer, showcasing AbbVie's innovations in targeted therapies.
  • Venclexta/Venclyxto: Offers hope for patients battling blood cancers, through a regimen that interferes with cancer cell survival.
  • Aesthetic Products: A range of facial injectables, plastics and regenerative medicine, body contouring, and skincare offerings that cater to aesthetic needs.
  • Botox Therapeutic: Beyond cosmetic applications, this product is utilized for various therapeutic purposes, enhancing patient care.
  • Vraylar: A medication designed to address depressive disorder, contributing to mental health treatment options.
  • Duopa and Duodopa: These formulations provide relief for patients with advanced Parkinson's disease, improving quality of life.
  • Ubrelvy and Qulipta: Target the acute treatment of migraine in adults, including both episodic and chronic forms.
  • Ozurdex: An ocular implant designed to treat eye diseases, emphasizing AbbVie's contribution to ophthalmology.
  • Lumigan/Ganfort and Alphagan/Combigan: Aimed at reducing intraocular pressure in conditions like open-angle glaucoma or ocular hypertension.
  • Restasis: Helps increase tear production, addressing the needs of patients with dry eye disease.
  • Mavyret/Maviret: Administered for the treatment of chronic hepatitis C virus (HCV) infection, representing a breakthrough in HCV treatment.
  • Creon: A pancreatic enzyme therapy essential for patients with pancreatic insufficiency, aiding digestion.
  • Lupron: Utilized for treating advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids-related anemia.
  • Linzess/Constella: Offers relief for irritable bowel syndrome with constipation and chronic idiopathic constipation.
  • Synthroid: A synthetic thyroid hormone used to treat hypothyroidism, ensuring thyroid hormone levels are balanced.

Contact Information

Address: 1 North Waukegan Road
Phone: 847 932 7900